# EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

Study · id `cardio:ct-nct05584319` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05584319](<https://clinicaltrials.gov/study/NCT05584319>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05584319

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05584319. Randomized; no masking; primary purpose treatment. Start 2022-12-15 (anticipated); primary completion 2024-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05584319, source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)
- Planned start: 2022-12-15 (anticipated) (ClinicalTrials.gov record NCT05584319, source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)
- Primary completion: 2024-10 (anticipated) (ClinicalTrials.gov record NCT05584319, source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)
- Completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT05584319, source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05584319, source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05584319-2022-12-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
- Condition: Heart Failure
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): Empagliflozin 10 Mg
- Lead sponsor: Zhijun Sun
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Zhijun Sun (`cardio:org-zhijun-sun`)

## Provenance

Content hash: b760d0ce9d1409e89dd89cd0a2b1fad6d37febdd284aff153811fa24d72908b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
